While GLP-1s like Ozempic and Wegovy are being widely prescribed for weight loss, doctors currently do not have a way to ...
A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...
Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...
GLP-1S HAVE BEEN called “wonder drugs” for how they have revolutionized weight loss, and they’re being explored for their ...
UCSF experts share their research on medications’ potential to slow or reduce risk of dementia and to treat the triggers that ...
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced two ...
Oral GLP-1s are set to shake up the weight-loss drug market, but industry onlookers will be wondering how these new tablets might impact healthcare supply chains.
A majority of GLP-1 lawsuits come from patients who allege that manufacturers have inadequately warned about severe side ...
The Centers for Medicare & Medicaid Services will launch the Medicare GLP-1 Bridge in July 2026, offering some Part D beneficiaries temporary access to GLP-1 drugs for weight loss alongside coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results